Bayer Sees Slow Growth; Targets Higher Pharma Rank

Bayer says its fourth-quarter and full-year 2011 results, announced on February 28, were a success despite a challenging economic environment. The company also provided guidance for 2012, saying that it expects sales to increase by about 3% with “slight improvements in Ebitda before special items and core earnings per share.” Dekkers: Good pharma pipeline. Thomas: Chinese growth slowed. Bayer’s fourth-quarter net income reached €397 million ($534.1 million), compared with a loss of €145 million in the year-earlier period. Sales were...

This information is only available to Chemical Week subscribers.

Forgot your user ID or password?
Click here to have it sent to you.

Email Address First Name Last Name

Not an IHS Chemical Week 24/7 member yet? Here's why you should be: Searchable online archive access of the last 2 years of Chemical Week. Print or digital magazine subscription Price and market change alerts Economic data and statistics Buyers' Guides Webcasts | whitepapers